Alladapt Immunotherapeutics, a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to address IgE-mediated food allergy, has initiated the buildout of a new state-of-the-art manufacturing facility to support future production of its lead product candidate, ADP101. ADP101 is a novel, investigational oral immunotherapy designed to address allergies to one or to multiple foods associated with 90% of severe reactions. The 53,000 square foot manuf...